ReviewAnnals of medicine and surgery (2012)2026
Nacubactam: a review on mechanistic insights and therapeutic promise for combating β-lactam resistance among multidrug-resistant Gram-negative pathogens.
Review in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The unprecedented rise of antimicrobial resistance has substantially compromised the efficacy of β-lactam antibiotics, once the cornerstone of bacterial infection management, posing a major challenge to modern medicine. β-Lactams exert their antibacterial effect by inhibiting penicillin-binding proteins (PBPs) involved in cell wall synthesis; however, resistance mechanisms including porin alterations, PBP mutations, β-lactamase production, and efflux systems increasingly limit their clinical utility. In response, the development of β-lactamase inhibitors (BLIs) has become a critical strategy, with diazabicyclooctanes such as nacubactam (NAC) representing a mechanistically distinct advancement. NAC is a non-β-lactam BLI that exhibits a unique multi-modal mechanism of action encompassing inhibition of serine β-lactamases (Ambler classes A, C, and selected D), direct binding to penicillin-binding protein 2 (PBP2), and enhancement of partner β-lactam activity, including in certain β-lactamase-negative strains. Preclinical
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.